The human microbiome and benign prostatic hyperplasia: Current understandings and clinical implications

Microbiol Res. 2024 Apr:281:127596. doi: 10.1016/j.micres.2023.127596. Epub 2024 Jan 3.

Abstract

The research of the human microbiome in the preceding decade has yielded novel perspectives on human health and diseases. Benign prostatic hyperplasia (BPH) is a common disease in middle-aged and elderly males, which negatively affects the life quality. Existing evidence has indicated that the human microbiome, including urinary, intra-prostate, gut, oral and blood microbiome may exert a significant impact on the natural progression of BPH. The dysbiosis of the microbiome may induce inflammation at either a local or systemic level, thereby affecting the BPH. Moreover, metabolic syndrome (MetS) caused by the microbiome can also be involved in the development of BPH. Additionally, alterations in the microbiome composition during the senility process may serve as another cause of the BPH. Here, we summarize the influence of human microbiome on BPH and explore how the microbiome is linked to BPH through inflammation, MetS, and senility. In addition, we propose promising areas of investigation and discuss the implications for advancing therapeutic approaches.

Keywords: Benign prostatic hyperplasia; Inflammation; Metabolic syndrome; Microbiome; Senility.

Publication types

  • Review

MeSH terms

  • Aged
  • Humans
  • Inflammation
  • Male
  • Metabolic Syndrome* / complications
  • Microbiota*
  • Middle Aged
  • Prostatic Hyperplasia* / etiology
  • Prostatic Hyperplasia* / metabolism